Literature DB >> 12652345

Behavioral, neuroendocrine and neurochemical effects of the imidazoline I2 receptor selective ligand BU224 in naive rats and rats exposed to the stress of the forced swim test.

David P Finn1, Octavi Martí, Michael S Harbuz, Astrid Vallès, Xavier Belda, Cristina Márquez, David S Jessop, Margaret D Lalies, Antonio Armario, David J Nutt, Alan L Hudson.   

Abstract

RATIONALE: There is evidence for alterations in imidazoline(2) (I(2)) receptor density in depressed patients. Selective I(2) receptor ligands modulate central monoamine levels and activate the hypothalamo-pituitary-adrenal (HPA) axis and may have potential as antidepressants.
OBJECTIVES: To study the behavioral effects of the selective I(2) receptor ligand BU224 in the rat forced swim test (FST) and its effects on the HPA axis and central monoaminergic responses.
METHODS: Rats received saline or BU224 (10 mg/kg IP) 24, 18 and 1 h prior to 15 min exposure to the FST. Saline- and BU224-treated non-stressed groups were included. Time spent immobile, struggling and swimming calmly was measured. Plasma adrenocorticotrophic hormone (ACTH) and corticosterone levels 90 min post-BU224 were measured in addition to tissue levels of monoamines and metabolites in the frontal cortex, hippocampus and hypothalamus.
RESULTS: Administration of BU224 significantly reduced immobility and increased mild swimming without affecting struggling. Exposure to the FST significantly increased plasma ACTH and corticosterone levels. BU224 administration also increased ACTH and potentiated the ACTH response to FST with no effect on corticosterone. BU224 administration significantly increased frontal cortex 5-hydroxytryptamine (5-HT) levels and decreased 5-HT turnover in the frontal cortex and hypothalamus of rats exposed to FST. In non-stressed rats, BU224 decreased 5-HT turnover in the hippocampus and hypothalamus and decreased norepinephrine turnover in the frontal cortex.
CONCLUSIONS: The selective I(2) receptor ligand BU224 reduces immobility of rats in the FST, indicative of antidepressant-like activity. This effect is accompanied by alterations in HPA axis and central monoaminergic activity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12652345     DOI: 10.1007/s00213-003-1392-3

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  58 in total

Review 1.  Noradrenergic mechanisms in the prefrontal cortex.

Authors:  D J Nutt; M D Lalies; L A Lione; A L Hudson
Journal:  J Psychopharmacol       Date:  1997       Impact factor: 4.153

2.  Differential responsiveness of inbred strains of rats to antidepressants in the forced swimming test: are Wistar Kyoto rats an animal model of subsensitivity to antidepressants?

Authors:  A Lahmame; A Armario
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

3.  Forced swim test-induced endocrine and immune changes in the rat: effect of subacute desipramine treatment.

Authors:  T J Connor; J P Kelly; B E Leonard
Journal:  Pharmacol Biochem Behav       Date:  1998-01       Impact factor: 3.533

Review 4.  The specificity of stress responses to different nocuous stimuli: neurosteroids and depression.

Authors:  B Dubrovsky
Journal:  Brain Res Bull       Date:  2000-04       Impact factor: 4.077

5.  HPA axis dysfunction in depression: correlation with monoamine system abnormalities.

Authors:  M C Mokrani; F Duval; M A Crocq; P Bailey; J P Macher
Journal:  Psychoneuroendocrinology       Date:  1997       Impact factor: 4.905

6.  Densities of I2-imidazoline receptors, alpha 2-adrenoceptors and monoamine oxidase B in brains of suicide victims.

Authors:  M Sastre; J A García-Sevilla
Journal:  Neurochem Int       Date:  1997-01       Impact factor: 3.921

7.  Regional differences in the effects of forced swimming on extracellular levels of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid.

Authors:  L G Kirby; A R Allen; I Lucki
Journal:  Brain Res       Date:  1995-06-05       Impact factor: 3.252

8.  Blockade of alpha 2-adrenoceptors stimulates basal and stress-induced adrenocorticotropin secretion in the developing rat through a central mechanism independent from corticotropin-releasing factor and arginine vasopressin.

Authors:  M Grino; O Paulmyer-Lacroix; M Faudon; M Renard; G Anglade
Journal:  Endocrinology       Date:  1994-12       Impact factor: 4.736

9.  Forced swimming test in rats: effect of desipramine administration and the period of exposure to the test on struggling behavior, swimming, immobility and defecation rate.

Authors:  A Armario; A Gavaldà; O Martí
Journal:  Eur J Pharmacol       Date:  1988-12-13       Impact factor: 4.432

10.  Imidazoline(2) (I(2)) binding site- and alpha(2)-adrenoceptor-mediated modulation of central noradrenergic and HPA axis function in control rats and chronically stressed rats with adjuvant-induced arthritis.

Authors:  D P Finn; M D Lalies; M S Harbuz; D S Jessop; A L Hudson; D J Nutt
Journal:  Neuropharmacology       Date:  2002-06       Impact factor: 5.250

View more
  10 in total

1.  Striking variations in corticosteroid modulation of long-term potentiation along the septotemporal axis of the hippocampus.

Authors:  Nicola Maggio; Menahem Segal
Journal:  J Neurosci       Date:  2007-05-23       Impact factor: 6.167

2.  Plasticity of presynaptic and postsynaptic serotonin 1A receptors in an animal model of epilepsy-associated depression.

Authors:  Eduardo A Pineda; Julie G Hensler; Raman Sankar; Don Shin; Teresa F Burke; Andréy M Mazarati
Journal:  Neuropsychopharmacology       Date:  2011-02-23       Impact factor: 7.853

3.  Gender difference in epileptogenic effects of 2-BFI and BU224 in mice.

Authors:  Jia-Wei Min; Bi-Wen Peng; Xiaohua He; Yanan Zhang; Jun-Xu Li
Journal:  Eur J Pharmacol       Date:  2013-09-17       Impact factor: 4.432

4.  Postsynaptic alpha-2 adrenergic receptors are critical for the antidepressant-like effects of desipramine on behavior.

Authors:  Han-Ting Zhang; Lisa R Whisler; Ying Huang; Yang Xiang; James M O'Donnell
Journal:  Neuropsychopharmacology       Date:  2008-10-15       Impact factor: 7.853

5.  Behavioral effects of the imidazoline I(2) receptor ligand BU99006 in rats.

Authors:  Yanyan Qiu; David A Thorn; Yanan Zhang; Xiaohua He; Jun-Xu Li
Journal:  Behav Pharmacol       Date:  2014-04       Impact factor: 2.293

6.  Amelioration of BPSD-Like Phenotype and Cognitive Decline in SAMP8 Mice Model Accompanied by Molecular Changes after Treatment with I2-Imidazoline Receptor Ligand MCR5.

Authors:  Foteini Vasilopoulou; Andrea Bagan; Sergio Rodriguez-Arevalo; Carmen Escolano; Christian Griñán-Ferré; Mercè Pallàs
Journal:  Pharmaceutics       Date:  2020-05-23       Impact factor: 6.321

Review 7.  Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness.

Authors:  Jonathan Hamill; Jaime Hallak; Serdar M Dursun; Glen Baker
Journal:  Curr Neuropharmacol       Date:  2019       Impact factor: 7.363

8.  Identification of an imidazoline binding protein: creatine kinase and an imidazoline-2 binding site.

Authors:  Atsuko Kimura; Robin J Tyacke; James J Robinson; Stephen M Husbands; Michael C W Minchin; David J Nutt; Alan L Hudson
Journal:  Brain Res       Date:  2009-05-03       Impact factor: 3.252

9.  CR4056, a new analgesic I2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats.

Authors:  Cristina Meregalli; Cecilia Ceresa; Annalisa Canta; Valentina Alda Carozzi; Alessia Chiorazzi; Barbara Sala; Norberto Oggioni; Marco Lanza; Ornella Letari; Flora Ferrari; Federica Avezza; Paola Marmiroli; Gianfranco Caselli; Guido Cavaletti
Journal:  J Pain Res       Date:  2012-06-20       Impact factor: 3.133

10.  Astrocyte reactivity with late-onset cognitive impairment assessed in vivo using 11C-BU99008 PET and its relationship with amyloid load.

Authors:  Valeria Calsolaro; Paul M Matthews; Cornelius K Donat; Nicholas R Livingston; Grazia D Femminella; Sandra Silva Guedes; Jim Myers; Zhen Fan; Robin J Tyacke; Ashwin V Venkataraman; Robert Perneczky; Roger Gunn; Eugenii A Rabiner; Steve Gentleman; Christine A Parker; Philip S Murphy; Paul B Wren; Rainer Hinz; Magdalena Sastre; David J Nutt; Paul Edison
Journal:  Mol Psychiatry       Date:  2021-07-15       Impact factor: 15.992

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.